Janssen Pharma, Russia's NewVac To Develop Cancer-Treatment Drug
This article was originally published in PharmAsia News
Executive Summary
Janssen Pharmaceuticals and NewVac have signed an agreement to share development and marketing rights for the U.S. drug maker's quisinostat for treating solid tumors along with standard care in Eastern Europe.